- Raw materials
- Antibacterials
- Flurithromycin
Flurithromycin API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Flurithromycin | CAS No: 82664-20-8 | GMP-certified suppliers
A medication that provides systemic antibacterial activity with potential enzyme inhibition effects for managing bacterial infections in experimental therapeutic developments.
Therapeutic categories
Product Snapshot
- Flurithromycin is an oral small molecule available in tablet and coated tablet formulations
- It is primarily investigated for antimicrobial therapeutic applications
- The compound is currently in an experimental approval status with no established regulatory approvals
Clinical Overview
The compound’s documented classification includes enzyme inhibition properties, particularly against cytochrome P450 isoforms CYP3A and CYP3A4. This suggests that flurithromycin may influence the metabolism of co-administered drugs metabolized by these enzymes, although specific data on the extent of such interactions remain to be fully elucidated.
Flurithromycin is currently experimental and lacks a formally established clinical indication. As such, comprehensive pharmacodynamic and mechanistic profiles have not been definitively described in the literature. Macrolides typically exert antibacterial effects by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis; flurithromycin is presumed to act via a similar mechanism consistent with its classification but confirmatory data are not available.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for flurithromycin have not been clearly defined. Given its classification, partial oral bioavailability and hepatic metabolism involving CYP enzymes can be anticipated. The inhibitory effect on CYP3A/3A4 may further influence its own metabolism and that of other substrates in clinical contexts.
Safety and toxicity data are limited due to the experimental status of the compound. Standard macrolide-related adverse effects, such as gastrointestinal disturbances and potential hepatotoxicity, may be of concern. The inhibitory action on CYP enzymes also raises the possibility of drug-drug interactions requiring careful evaluation.
There are no notable marketed brands or widespread clinical use reported for flurithromycin at this time. When sourcing the flurithromycin API, quality considerations should include verification of chemical purity, consistent stereochemistry, and absence of residual solvents, in compliance with regulatory standards for experimental pharmaceuticals. Batch-to-batch consistency and characterization of impurity profiles are critical to support research and potential future clinical development.
Identification & chemistry
| Generic name | Flurithromycin |
|---|---|
| Molecule type | Small molecule |
| CAS | 82664-20-8 |
| UNII | 56C9DTE69V |
| DrugBank ID | DB13338 |
Formulation & handling
- Flurithromycin is administered orally, primarily in tablet form including coated tablets.
- As an aminoglycoside small molecule with moderate water solubility, attention to dissolution and bioavailability during formulation is important.
- The compound’s moderate LogP suggests balanced hydrophilic-lipophilic properties influencing absorption and distribution.
Regulatory status
Flurithromycin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
